DNLI’s Recent Pipeline Updates - Yahoo Finance
1 day ago · dnli Denali Therapeutics Inc . Denali’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development ...
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus ...
12 hours ago · Read Our Latest Analysis on DNLI Insider Activity at Denali Therapeutics. 3 Mid-Cap Biotechs Analysts Think Can Double; In related news, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00.
Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote
Find the latest Denali Therapeutics Inc. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing.
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy …
2 days ago · SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Denali Therapeutics Inc. (DNLI) Latest Stock News & Headlines
Get the latest Denali Therapeutics Inc. (DNLI) stock news and headlines to help you in your trading and investing decisions.
Denali Therapeutics (DNLI) Stock Price, News & Analysis
2 days ago · Should You Buy or Sell Denali Therapeutics Stock? Get The Latest DNLI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.
DNLI Stock Price | Denali Therapeutics Inc. Stock Quote ... - MarketWatch
2 days ago · DNLI | Complete Denali Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Denali Therapeutics announces HEALEY ALS trial ... - Markets Insider
3 days ago · Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic ...
Denali Therapeutics Announces Topline Results for Regimen G …
3 days ago · SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Denali Therapeutics Inc. (DNLI) Latest Stock News - Seeking Alpha
2 days ago · Get the latest news and real-time alerts from Denali Therapeutics Inc. (DNLI) stock at Seeking Alpha.
- Some results have been removed